Your browser doesn't support javascript.
Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction.
Hoff, Norman-Philipp; Freise, Noemi F; Schmidt, Albrecht G; Firouzi-Memarpuri, Parnian; Reifenberger, Julia; Luedde, Tom; Bölke, Edwin; Meller, Stephan; Homey, Bernhard; Feldt, Torsten; Jensen, Björn Erik Ole; Keitel, Verena; Schmidt, Livia; Maas, Kitti; Haussmann, Jan; Tamaskovics, Balint; Budach, Wilfried; Fischer, Johannes C; Buhren, Bettina Alexandra; Knoefel, Wolfram Trudo; Schneider, Marion; Gerber, Peter Arne; Pedoto, Alessia; Häussinger, Dieter; Grebe, Olaf; van Griensven, Martijn; Braun, Stephan A; Salzmann, Stefan; Rezazadeh, Amir; Matuschek, Christiane.
  • Hoff NP; Department of Dermatology, University Hospital Düsseldorf, Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany.
  • Freise NF; Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
  • Schmidt AG; Department of Radiation Oncology, University Hospital Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany.
  • Firouzi-Memarpuri P; Department of Dermatology, University Hospital Düsseldorf, Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany.
  • Reifenberger J; Department of Dermatology, University Hospital Düsseldorf, Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany.
  • Luedde T; Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
  • Bölke E; Department of Radiation Oncology, University Hospital Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany. boelke@med.uni-duesseldorf.de.
  • Meller S; Department of Dermatology, University Hospital Düsseldorf, Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany.
  • Homey B; Department of Dermatology, University Hospital Düsseldorf, Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany.
  • Feldt T; Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
  • Jensen BEO; Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
  • Keitel V; Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
  • Schmidt L; Department of Radiation Oncology, University Hospital Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany.
  • Maas K; Department of Radiation Oncology, University Hospital Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany.
  • Haussmann J; Department of Radiation Oncology, University Hospital Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany.
  • Tamaskovics B; Department of Radiation Oncology, University Hospital Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany.
  • Budach W; Department of Radiation Oncology, University Hospital Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany.
  • Fischer JC; Institute for Transplant Diagnostics and Cell Therapeutics, Heinrich Heine University, Düsseldorf, Germany.
  • Buhren BA; Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany.
  • Knoefel WT; Department of Surgery and Interdisciplinary Surgical Intensive Care Unit Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
  • Schneider M; Division of Experimental Anesthesiology, University Hospital Ulm, Ulm, Germany.
  • Gerber PA; Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany.
  • Pedoto A; Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Häussinger D; Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
  • Grebe O; Department of Cardiology and Rhythmology, Petrus Hospital, Wuppertal, Germany.
  • van Griensven M; Department cBITE, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, The Netherlands.
  • Braun SA; Department of Dermatology, University Hospital Düsseldorf, Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany.
  • Salzmann S; Department of Dermatology, University Hospital Münster, Münster, Germany.
  • Rezazadeh A; Department of Dermatology, University Hospital Münster, Münster, Germany.
  • Matuschek C; Department of Radiation Oncology, University Hospital Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany.
Eur J Med Res ; 26(1): 98, 2021 Aug 25.
Article in English | MEDLINE | ID: covidwho-1371980
ABSTRACT

BACKGROUND:

The coronavirus disease 2019 (COVID-19) is associated with a wide clinical spectrum of skin manifestations, including urticarial, vesicular, vasculitic and chilblain-like lesions. Recently, delayed skin reactions have been reported in 1% individuals following mRNA vaccination against SARS-CoV-2. The exact pathophysiology and the risk factors still remain unclear. PATIENTS AND

METHODS:

6821 employees and patients were vaccinated at our institutions between February and June 2021. Every patient received two doses of the mRNA-1273 vaccine in our hospitals, and reported back in case of any side effects which were collected in our hospital managed database.

RESULTS:

Eleven of 6821 vaccinated patients (0.16%) developed delayed skin reactions after either the first or second dose of the mRNA-1273 vaccine against SARS-CoV-2. Eight of 11 patients (73%) developed a rash after the first dose, while in 3/11 (27%), the rash occurred after the second dose. More females (9/11) were affected. Four of 11 patients required antihistamines, with two needing additional topical steroids. All the cutaneous manifestations resolved within 14 days. None of the skin reactions after the first dose of the vaccine prevented the administration of the second dose. There were no long-term cutaneous sequelae in any of the affected individuals.

CONCLUSION:

Our data suggests that skin reactions after the use of mRNA-1273 vaccine against SARS-CoV-2 are possible, but rare. Further studies need to be done to understand the pathophysiology of these lesions.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatitis / Erythema / COVID-19 Vaccines / COVID-19 Type of study: Risk factors Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Eur J Med Res Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: S40001-021-00557-Z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatitis / Erythema / COVID-19 Vaccines / COVID-19 Type of study: Risk factors Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Eur J Med Res Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: S40001-021-00557-Z